Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

What do GMP inspectors really check in pharmaceutical water systems? Explore critical PW and WFI requirements, validation gaps, microbial risks, and recurring FDA findings. Discover practical inspection checkpoints and strategies to maintain compliance and protect product quality.
From water for injection to clean steam, HVAC, and process gases, pharmaceutical utilities carry hidden GMP risks. Explore what inspectors examine, how systems are qualified, and which monitoring controls maintain compliance throughout the manufacturing lifecycle.
From early facility decisions to requalification, small engineering gaps can become costly GMP findings. Explore how risk-based design, commissioning, equipment qualification, maintenance, and change control build inspection-ready systems—and what regulators expect to see in the supporting records.
What does it take to satisfy two regulatory frameworks with one quality system? Explore how pharma consultancy in Indore helps Pithampur manufacturers address USFDA scrutiny, revised Schedule M, validation gaps, and data integrity risks before inspections begin.
Indian drug regulators have inspected over 1,040 sites, and Revised Schedule M now makes WHO-aligned GMP the legal baseline. Learn how to judge pharma consulting companies in India by what still holds when the inspector walks in.
Since QMSR took effect in February 2026, FDA inspectors can review internal audits and management reviews. Learn what FDA IVD guidance expects, from 510(k) pathways and analytical validation to labeling, LDT status and the Form 483 gaps investigators cite most.
IVD regulations now decide market access in both the EU and US. Learn how notified bodies test classification, performance evaluation and transition status, where IVDR and FDA requirements differ, and which compliance gaps auditors’ flag most often.
IVD registration under the EU IVDR demands more than paperwork. Discover how risk classification, performance evaluation, CE marking, and EUDAMED requirements shape market access, and learn the essential steps to avoid costly regulatory delays and certification setbacks.
Learn how ANVISA classifies medical devices, when notification or registration applies, and what manufacturers need for BGMP, local representation, technical documentation, and market access. This guide helps teams avoid common submission delays and plan a clearer regulatory pathway in Brazil.
Entering Saudi Arabia’s medical device market requires more than submitting an application. Explore SFDA classification, MDMA registration, authorized representative licensing, QMS evidence, inspection findings, and post-market obligations to understand what manufacturers need for compliant market access.